News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SGMO new 52 week low
I quite agree with your assessment of clinical stage bio companies as expensive experiments.
Out of curiosity I checked the reverse stock split history for Sangamo and came up with zero, which I found interesting.
Ever since Amgen went public in 1984 investors have placed high hopes on the possibility of hitting the Big One.
The biotech, biomed, medical device sector is actually the largest sector in terms of available public traded companies in which one
can invest. More go public every week.
The stock has certainly experienced some dramatic ups and downs since 2000
SGMO new 52 week low
Over 28 years with no success, allowing others to overtake them, while they created an unsustainable infrastructure. They couldn't even license their AAV capsids or ZFP-TFs, instead having to settle for a nominal "evaluation agreements" with Prevail and Chroma.
Worse still, have around a year of cash on hand unless they decide to address their costs. Does anyone know when the company plans on breaking even? Will it be in '26 or '27 if their haemophilia therapy is approved in '25? Also, they will need to rise, and with the current price it's going to be (extremely) dilutive. If the therapy isn't approved, I don't see how the company isn't toast.
SGMO new 52 week low
SGMO new 52 week low
SGMO new 52 week low
SGMO new 52 week low
SGMO new 52 week low
Deep Pipeline blockbuster potential across the board.
Major partnerships.
Lots of headwinds entering 2023 Looking for substantial gains from here.
Chart just turned bullish.
$SGMO
Good call but hard to say what it is doing this week, all the ARKG stocks pulled back hard...
$SGMO I have a lot of Calls! Outpreforming the sector. Maybe ARK is coming in...
I think it can be $25 in the blink of an eye. The sector is hot, might see $25 next week...
$SGMO I have a good feeling about this one.
Wonder if $ARKG is considering buying?
$SGMO I reloaded on the dip today, looks like it could go a lot higher...
|
Followers
|
74
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
438
|
|
Created
|
09/09/04
|
Type
|
Free
|
| Moderators | |||
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
